Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Integration of efficient downstreaM PRocessEs for Sugars and Sugar alcohols (IMPRESS)

Framework: Horizon 2020 — Industrial Leadership
Programme: Nanotechnologies, Advanced Materials, Advanced Manufacturing and Processing, and Biotechnology
Theme: Sustainable, resource-efficient and low-carbon technologies in energy-intensive process industries
Action type: Innovation actions
Countries involved: Germany,Austria,Germany,Finland,Finland,Switzerland,France,Netherlands,Netherlands,Netherlands
Call: Efficient integrated downstream processes (IA) (H2020-NMBP-SPIRE-2019, 2019)
Start date: 2019-09-01
End date: 2024-02-29
Duration (months): 54.0
Total project cost (EUR): 17867930.0
EU funding (EUR): 13322632.629999999
Participants: 12
Project status: SIGNED

The IMPRESS project will demonstrate a new hybrid biorefinery process for the first time, integrating disruptive upstream and downstream technologies developed by the project partners. A main objective of the project is to develop and upscale separation and purification methods for the upstream process and modular downstream processes. New purification and separation methods will enable to produce new products, like xylitol, erythritol, bio-based ultra pure monoethylene glycol and monopropylene glycol and lignin derived activated carbon. All the process routes developed and up-scaled in the project are integrated to the IMPRESS concept by executing a Conceptual Process Design (CPD) of the different unit operations and then the CPD of integrated IMPRESS concept. It’s expected that the new purification and separation methods, and new high value products combined with benefits deriving from the integration will decrease OPEX by by 25 % and CAPEX by 20 %. In addition, the GHG emissions are expected to decrease more than 20 %. The decrease of CAPEX and OPEX will be calculated by CPD and the environmental performance of the IMPRESS concept and the developed products are evaluated by performing a Life Cycle Assessment (LCA). The results of the project and benefits of the IMPRESS concept will be disseminated to relevant stakeholders by preparing education modules concerning individual unit operations, the integrated process, and methodology such as LCA that will be easily integrated in existing curricula and modules for undergraduate level and lifelong learning programmes.

Keywords: integration,unit operations,separation,purification,glucose,carbohydrates,sweeteners,lignin
Ultrafast Raman Technologies for Protein Identification and Sequencing (ProID)

Framework: Horizon 2020 — Excellent Science
Programme: Future and Emerging Technologies (FET)
Theme: EIC Pathfinder
Destination: Novel ideas for radically new technologies
Action type: Research and Innovation actions
Countries involved: Germany,Italy,Italy,Germany,Italy,Italy,Sweden,France,Luxembourg
Call: FET-Open Challenging Current Thinking (H2020-FETOPEN-2018-2019-2020-01, 2020)
Start date: 2021-05-01
End date: 2024-10-31
Duration (months): 42.0
Total project cost (EUR): 2988513.75
EU funding (EUR): 2988513.75
Participants: 9
Project status: SIGNED

The human proteome is the whole set of protein that a human can potentially express. Most of the human proteome is known. However the proteome, being the set of proteins potentially expressed, does not give information regarding the protein really expressed in a specific person or a patient. The possibility of accessing to this fundamental information through a cost and time effective technique will revolutionize our ability to prevent, diagnose and treat most of the human diseases. This is the commitment of ProID that aims to provide a technological platform able to record single protein Raman spectra with single amino-acid resolution. Namely, by reading the sequence of selected amino-acids along the protein chain, the platform will identify the corresponding protein. To reach this goal we want to combine advanced nanofabrications of plasmonic nanopores with ultrafast time resolved photon detectors and machine learning algorithms. More in details: i) plasmonic nanopores will be exploited to achieve single amino-acid optical excitation and enhanced Raman stimulation; ii) ultrafast and ultrasensitive Raman spectrometers will be obtained by combining the emerging technologies of SPAD (Single Photon Avalanche Diode) arrays with dedicated otpica elements which improve the sensitivity and the speed of the detector, and reduce the number of elements of the array necessary to sample a Raman spectrum; iii) bioinformatics approaches will complete the technological platform by developing specific software for discriminating the Raman spectra of proteins with reduced spectral points. Also, insightful experiments on electrophoretic translocation and augmented fluid viscosity in ultra-confined systems will contribute the molecular motion into the nanopores. Finally, to state of the art in-silico design will support the project by contributing to system optimization and data analyses/interpretation.

Keywords: raman,single photon detector,spad array,bioinformatics,single molecule detection
Inter-individual variability in learning: an investigation of its determinants (LearningDeterminants)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Global Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Switzerland,France
Call: Marie Skłodowska-Curie Individual Fellowships (IF-GF) (H2020-MSCA-IF-2014, 2014)
Start date: 2015-05-01
End date: 2018-04-30
Duration (months): 36.0
Total project cost (EUR): 261957.6
EU funding (EUR): 261957.6
Participants: 2
Project status: CLOSED

The ability to extract regularities from the environment (statistical learning) is an essential feature of the primate brain. While inter-individual differences exist in statistical learning capacity in humans, little is know as to their origins. The present project proposes to investigate the cognitive and neural determinants of these differences, and to ask what their impact might be on the acquisition of a foundational skill for education, i.e. reading. To this end, we will first assess performance in two statistical learning tasks and various cognitive tests in a large group of adults (N=500). Based on the literature and on preliminary results from the outgoing host lab, we predict a link between learning and attention. We will further test this hypothesis by examining statistical learning in a population with high attentional abilities, namely action video gamers. Second, in an fMRI experiment, we will use state-of-the-art analyses to evaluate the hypothesis of a distinct contribution of the hippocampus and of the fronto-striatal networks to learning across participants. Finally, we will estimate statistical learning ability in pre-readers and longitudinally assess its predictive value on reading skills, as subsequently measured in first grade. Both the project’s core questions and the methods chosen to address them are highly innovative and inter-disciplinary, spanning fields as disparate as cognitive sciences, neuroscience, development and education. The project is expected to have a crucial impact on the applicant’s career, by broadening her experimental skills and scientific horizons, and giving her a chance to run her own study, a first step towards the objective of obtaining an independent position in research. Finally, by strengthening collaborations between partners in and outside Europe, and by taking a grip on timely questions mainly addressed outside of ERA for now, this project is expected to contribute to European research excellence.

Keywords: learning,individual differences,functional mri,development
Moving to Efficient Diabetes care: Multimode Integrated CO-morbidity diagnostics platform (MEDMICO)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Treating and managing disease
Action type: SME instrument
Countries involved: Ireland
Call: Clinical research for the validation of biomarkers and/or diagnostic medical devices (H2020-SMEINST-2-2014, 2014)
Start date: 2015-07-01
End date: 2018-12-31
Duration (months): 42.0
Total project cost (EUR): 4487525.0
EU funding (EUR): 4487525.0
Participants: 1
Project status: CLOSED

Diabetes affects 8.5% (2013) of the adult European population rising to 10.3% (2035) and is associated with co-morbid conditions such as cardiovascular and renal abnormalities. These lead to diabetic complications, ischemic heart disease, heart failure and kidney failure. Management of this growing epidemic requires a shift in care management and delivery, away from lab testing. The majority of current diagnostic testing for diabetes and comorbidities involves central laboratories as incumbent in-vitro diagnostic point-of-care testing (PoCT) provides sub-optimal accuracy and single tests (rather than needed panels) for diabetes and its comorbidities. MEDMICO will spearhead a diagnostic breakthrough by delivering the 1st quad-mode PoCT platform integrating immunoassays, turbidimetry, clinical chemistry and cell counting. HbA1c, Lipids and Creatinine tests will be integrated on to a single diabetes comorbid platform with state-of-the-art sensitivity/precision, room temperature storage, >12 months’ shelf-life and integrated pipette to screen, diagnose and monitor patients, within primary care, outpatient clinics and pharmacies. This will improve patient outcomes and healthcare efficiencies, positioning Europe at the forefront of healthcare innovation and deliver an efficient platform to combat this epidemic. MEDMICO incorporates extensive technical, clinical and exploitation expertise - Radisens’ disruptive PoCT prototype and Trinity College Dublin (sub-contractor) biomaterials expertise and diabetes patient access. MEDMICO’s potential is evidenced by Radisens’ revenues to date and large near-term projections from diagnostics partners before its launch. Existing research of end-user needs and workflow assessment will drive platform development and pilot production, with clinical validation and usability trials in multiple PoCT segments to TRL8. This will deliver a validated quad-mode diabetes comorbidity platform, ready for regulatory submission.

Keywords: diabetes comorbidity cardiovascular renal multimode poct
Strategic Dialogue on Sustainable Raw Materials for Europe (STRADE)

Framework: Horizon 2020 — Societal Challenges
Programme: Climate action, environment,  resource efficiency and raw materials
Theme: Ensuring the sustainable supply of non-energy and non-agricultural raw materials
Action type: Coordination and support actions
Countries involved: South Africa,Germany,Germany,Sweden,Sweden,United Kingdom,United Kingdom
Call: Strategic international dialogues and cooperation with raw materials producing countries and industry (H2020-SC5-2015-one-stage, 2015)
Start date: 2015-12-01
End date: 2018-11-30
Duration (months): 36.0
Total project cost (EUR): 1977508.75
EU funding (EUR): 1977508.75
Participants: 8
Project status: CLOSED

STRADE addresses the long-term security and sustainability of the European raw material supply from European and non-European countries. It will develop dialogue-based, innovative policy recommendations for a European strategy on future raw-material supplies. STRADE will initially concentrate on the industry perspective. Based on an analysis of the European mineral raw-material mining sector’s competitiveness, the objective is to provide a strategy on how the EU can work to promote mining investment into and within the EU. Areas in which there is a need to revisit and improve present policies and conditions to advance European competitiveness for inward investments will be identified. STRADE also addresses equipment and service suppliers, exploration companies and investors. EU-level dialogues should be initiated with mineral-producing countries to support European businesses in these sectors within non-EU countries. These activities will also serve as a gateway to future cooperation between the EU and other raw-material-producing countries and will often address environmental challenges in the mining sector. Subsequently, STRADE will focus on government level and the EU’s relation to mineral-producing countries. Based to the mapping of present EU and member-state engagements as well as those engagements of non-EU countries, it will provide analyses on how the EU can renew its engagement with mineral-producing countries aiming at a larger EU strategy to ensure fair and unrestricted access to mineral raw materials worldwide. A specific objective towards the goals of environmental and social sustainability is the development of new concepts for Europe’s role in international action towards sustainable mining and processing. Stakeholder workshops on possible contributions of EU /member states to an international resource governance alliance and internationally accepted sustainability evaluation and certification schemes will be conducted.

Keywords: mineral economics,sustainable mining,supply security
Nerve-on-Chips (NOC)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Treating and managing disease
Action type: SME instrument
Countries involved: France
Call: Supporting innovative SMEs in the healthcare biotechnology sector (H2020-SMEINST-1-2016-2017, 2016)
Start date: 2016-12-01
End date: 2017-05-31
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

Neurodegenerative diseases (“ND”) are devastating as they cause individuals to lose their memories, independence, and ultimately, their lives. In the absence of drugs able to cureor prevent start of ND, the latter are a human and financial burden for individual patients, their relativesthe health care system and society in general. The worldwide economic impact of ND is evaluated at $2 trillion a year. The incidence of ND is expected to grow in the coming few years as life expectancy increases. In 2020, over 65 million people will suffer from Alzheimer Disease worldwide (over 6.5 million in the EU). MicroBrain Biotech is an innovative biotech startup founded in 2014. MBBT aims at offering “turn-key solutions” to biopharmaceutical research which will take the shape of microfluidic chips offering different types of reconstructed neuron networks at the micron scale. These chips are called Nerve-on-Chips (“NoC”, subcategory of Organ-on-Chips), and they simulate the function of tissues and organ subunits. Our patented NOC technology provides many advantages over other in vitro models such as conventional two-dimensional (2D) and tri-dimensional (3D) culture systems, over organoids, and over animal models: - Reduce biopharmaceutical R&D costs and increased efficiency in clinical research (improved competitiveness) - Reduce animal testing - Predicting human-relevant drug responses - Compatibility with readouts used in biology & real time visualization - Reconstitution of complex organ-level physiological functions NOC will allow to reduce drug R&D costs by 15% which will generate a total turnover worth €30 million. MBBT’s objective is to reach a €2 million worth turnover (i.e.: 8% OOC market share) within the 3 next years. The feasibility study will allow us to ensure IP policy (improvement patent, purchase of licenses) while assessing the market (supply chain, drug agencies, competitors, clients…) and validating the technological and biological approach.

Keywords: microfluidics,nerve on chips,brain on chips,organ on chips,neurodegenerative diseases,pharmacology,toxicology,alternative to animal testing,drug candidates,drug development,cost efficiency
The role of the serotonin 5-HT4 receptor in motor and non-motor symptoms of Parkinson’s disease (HT4PD)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Career Restart panel
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: France
Call: Individual Fellowships (H2020-MSCA-IF-2019, 2019)
Start date: 2021-01-01
End date: 2023-12-31
Duration (months): 36.0
Total project cost (EUR): 295061.76
EU funding (EUR): 295061.76
Participants: 1
Project status: SIGNED

Parkinson’s Disease (PD) is caused by dopaminergic neuron loss resulting in motor symptoms that are treated with L-DOPA. However, ≤90% of patients develop involuntary movements, termed L-DOPA induced dyskinesia (LID). Another less well studied, but highly occurring PD symptom is depression. There is evidence that the serotonin system is implicated in both, LID and PD-linked depression. Serotonergic (5-HT) neurons uncontrollably release L-DOPA-derived dopamine, and HTR1a/b agonists counteract such release and LIDs. Serotonin re-uptake inhibitors (SSRIs) also attenuate LID, through a still unknown mechanism. The striatally enriched Gαs-coupled receptor, HTR4, has the potential to enhance excitability of spiny projection neurons, to affect the balance of striatal pathways that is disrupted in PD and is a candidate to modulate LID and PD-depression. D2 agonists reduce depressive behavior in PD models, pointing towards a role for the striatum. Specifically, the dorsolateral striatum shows diminished metabolism, in contrast to non-PD-depression where the ventral striatum is a substrate. HTR4 in cortex and hippocampus was linked to antidepressant action. Agonists and overexpression yield anti-depressant-like responses, however, striatal HTR4 in PD-depression has not been examined. 1. We will determine HTR4 protein expression on a cellular level (dSPNs, iSPNs) in transgenic mice. We will virally overexpress, knockdown and pharmacologically manipulate HTR4 and assess striatally-driven behaviors. 2. We will probe HTR4 in motor symptoms by altering expression/activity in unilaterally 6-OHDA lesioned mice. We will evaluate LID onset/severity, dyskinesia markers and LTP, depotentiation and LTD. 3. We will test bilaterally-lesioned mice with altered HTR4 expression/activity in depression/anxiety paradigms. We will determine the effect on the action of D2, HTR1a agonists and SSRIs. Our comprehensive investigation of HTR4 will lead to a new understanding and treatment of PD.

Keywords: dopamine,serotonin,htr4,striatum,basal ganglia
Groups, Actions and von Neumann algebras (GAN)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Mathematics
Panel description: All areas of mathematics, pure and applied, plus mathematical foundations of computer science, mathematical physics and statistics
Countries involved: France,France
Call: ERC Starting Grant (ERC-2014-STG, 2014)
Start date: 2015-04-01
End date: 2020-03-31
Duration (months): 60.0
Total project cost (EUR): 876750.0
EU funding (EUR): 844473.75
Participants: 3
Project status: CLOSED

This research project focuses on the structure, classification and rigidity of three closely related objects: group actions on measure spaces, orbit equivalence relations and von Neumann algebras. Over the last 15 years, the study of interactions between these three topics has led to a process of mutual enrichment, providing both striking theorems and outstanding conjectures. Some fundamental questions such as Connes' rigidity conjecture, the structure of von Neumann algebras associated with higher rank lattices, or the fine classification of factors of type III still remain untouched. The general aim of the project is to tackle these problems and other related questions by developing a further analysis and understanding of the interplay between von Neumann algebra theory on the one hand, as well as ergodic and group theory on the other hand. To do so, I will use and combine several tools and develop new ones arising from Popa's Deformation/Rigidity theory, Lie group theory (lattices, boundaries), topological and geometric group theory and representation group theory (amenability, property (T)). More specifically, the main directions of my research project are: 1) The structure of the von Neumann algebras arising from Voiculescu's Free Probability theory: Shlyakhtenko's free Araki-Woods factors, amalgamated free product von Neumann algebras and the free group factors. 2) The structure and the classification of the von Neumann algebras and the measured equivalence relations arising from lattices in higher rank semisimple connected Lie groups. 3) The measure equivalence rigidity of the Baumslag-Solitar groups and several other classes of discrete groups acting on trees.

Keywords: msc2010 46lxx selfadjoint operator algebras,22dxx locally compact groups and their algebras,22exx lie groups,37axx ergodic theory
Towards Precision Psychiatry (ToPP)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Norway
Call: Individual Fellowships (H2020-MSCA-IF-2019, 2019)
Start date: 2020-08-01
End date: 2022-07-31
Duration (months): 24.0
Total project cost (EUR): 202158.72
EU funding (EUR): 202158.72
Participants: 1
Project status: CLOSED

The intricacies of the human mind and its disorders are one of the remaining modern-day enigmas. Whereas recent advances in brain imaging and genetics are currently changing the clinical neurosciences by identifying novel general mechanisms of complex traits underlying risk and resilience at the group level, our understanding of individual-level causes and mechanisms of mental disorder has remained almost unchanged which is important because clinical management must be performed at the individual level. During the Marie Sklodowska Curie Actions-Standard European-Individual Fellowship (MSCA-SE-IF) I will address this challenge. Initially, I will expand our innovative normative modeling framework to incorporate information on degree of genetic relatedness (Genetic Normative Model). Similar to growth charts in pediatrics, for which a child’s height is compared to the normative height at her/his age, we describe the distance of each individual in reference to the empirical population/healthy norm of a biological process. We compute this distance while also incorporating information on relatedness quantified by bioinformatic tools based on single-nucleotide polymorphisms across the genome or familiar relationships. We apply this approach in two discrete ways. First, we map the distance between individuals in reference to this norm based on their degree of genetic relatedness (Genetic Mapping), and second, we place individuals showing symptoms of mental disorders in reference to the estimated norm. In this way we can dissect pathophysiological mechanisms on a case by case basis (Disorder Mapping). This individualized approach has the potential to revolutionize our understanding of the heterogeneous mechanisms modulating risk and resilience of mental disorders and requires a joint effort across disciplines. Therefore, while hosted at NORMENT, a center of excellence in Norway, I will spend a secondment at the University of Oxford mentored by world leading experts.

Keywords: brain imaging,imaging genetics,mental disorders,precision medicine,big data analytics